The US Food and Drug Administration has issued an import alert on medicines made by Indian drugmaker Wockhardt (BSE: WOCK).
The alert concerned the company’s Chikalthana plantand five drugs produced there: bethanechol for urinary retention, antibiotic ceftriaxone, Enalapril Maleate - an antihypertensive, anticonvulsant/ anti-seizure medication divalproex sodium and antidepressant Venlafaxine Hydrochloride.
Wockhardt shares fell 8.3% to 430.75 rupees at the close in Mumbai trading, reported Bloomberg.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze